BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8626127)

  • 1. Molecular biology in the clinicopathologic assessment of endometrial carcinoma subtypes.
    Boyd J
    Gynecol Oncol; 1996 May; 61(2):163-5. PubMed ID: 8626127
    [No Abstract]   [Full Text] [Related]  

  • 2. [The regulation of estrogen and tamoxifen to bcl-2 oncogene in endometrial carcinoma].
    Lai D; Zhu G; Zhou J
    Zhonghua Fu Chan Ke Za Zhi; 1999 Oct; 34(10):615-7. PubMed ID: 11477803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCL-2 and P53 expression in endometrial carcinoma.
    Erkanli S; Eren F; Pekin S; Bagis T
    J Exp Clin Cancer Res; 2004 Mar; 23(1):97-103. PubMed ID: 15149157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of bcl-2, bax-xL, and bcl-xS in endometrial and cervical tissues.
    Mozzetti S; Ferrandina G; Marone M; D'Ingiullo F; Fruscella E; De Pasqua A; Mancuso S; Scambia G
    Cancer Detect Prev; 2000; 24(6):536-41. PubMed ID: 11198267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bcl-2 gene expression in endometrial carcinoma].
    Sheng X; Song H; He X
    Zhonghua Zhong Liu Za Zhi; 1998 Sep; 20(5):365-6. PubMed ID: 10921033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer.
    Ramondetta L; Mills GB; Burke TW; Wolf JK
    Clin Cancer Res; 2000 Jan; 6(1):278-84. PubMed ID: 10656459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in the study of oncogenes and tumor suppressor genes in endometrial carcinoma].
    Xue FX; Zhu YX; Jiao SZ
    Zhonghua Fu Chan Ke Za Zhi; 1994 Sep; 29(9):559-62. PubMed ID: 7835134
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
    Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
    In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bax gene expression in endometrial carcinoma].
    Chao H; Sun J; Lu S
    Zhonghua Zhong Liu Za Zhi; 2001 May; 23(3):214-6. PubMed ID: 11783089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-alpha, and NF-kappaB in human endometrial hyperplasia and carcinoma.
    Vaskivuo TE; Stenbäck F; Tapanainen JS
    Cancer; 2002 Oct; 95(7):1463-71. PubMed ID: 12237915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL-2, BAX and P53 expression profiles in endometrial carcinoma as studied by real-time PCR and immunohistochemistry.
    Porichi O; Nikolaidou ME; Apostolaki A; Tserkezoglou A; Arnogiannaki N; Kassanos D; Margaritis L; Panotopoulou E
    Anticancer Res; 2009 Oct; 29(10):3977-82. PubMed ID: 19846939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of p53 protein in women with endometrial cancer].
    Ivanov S; Khadzhiolov N; Ivanov S
    Akush Ginekol (Sofiia); 2001; 40(4):14-5. PubMed ID: 11803862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen as a carcinogen: the genetics and molecular biology of human endometrial carcinoma.
    Boyd J
    Prog Clin Biol Res; 1996; 394():151-73. PubMed ID: 8778795
    [No Abstract]   [Full Text] [Related]  

  • 14. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
    Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
    Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A study on expression of tumor suppressor gene p53 in endometrial carcinoma].
    Xue F; Jiao S; Zhao F
    Zhonghua Fu Chan Ke Za Zhi; 1995 Nov; 30(11):647-50. PubMed ID: 8745486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
    Mirjolet JF; Barberi-Heyob M; Didelot C; Peyrat JP; Abecassis J; Millon R; Merlin JL
    Br J Cancer; 2000 Nov; 83(10):1380-6. PubMed ID: 11044365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables.
    Erdem O; Erdem M; Dursun A; Akyol G; Erdem A
    Int J Gynecol Pathol; 2003 Jul; 22(3):254-60. PubMed ID: 12819392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endometrial carcinoma: pathology and genetics.
    Prat J; Gallardo A; Cuatrecasas M; Catasús L
    Pathology; 2007 Feb; 39(1):72-87. PubMed ID: 17365824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. bcl-2 expression and the development of endometrial carcinoma.
    Chhieng DC; Ross JS; Ambros RA
    Mod Pathol; 1996 Apr; 9(4):402-6. PubMed ID: 8729980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas.
    Nikaido T; Li SF; Shiozawa T; Fujii S
    Cancer; 1996 Sep; 78(6):1248-53. PubMed ID: 8826947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.